Delta-Like Protein 4 antibody
Rabbit anti Human Dll4 antibody (AHP1274) used for the identification of Dll4 expressing cells in atherosclerotic plaques by immunohistochemistry.
Image caption:
Example of immunostaining of different antibodies.
A: Overview. C: CD68 positive macrophages. E: VEGFR2. F: VEGF. H: Dll4. Black bars represent 1000 μm (A) and 200 μm (B-H).
From: Hjelmgren O, Gellerman K, Kjelldahl J, Lindahl P, Bergström GML (2016)
Increased Vascularization in the Vulnerable Upstream Regions of Both Early and Advanced Human Carotid Atherosclerosis.
PLoS ONE 11(12): e0166918.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Rabbit anti Human Delta-like Protein 4 antibody detects human Delta-like protein 4 (DLL4), also known as Delta-4. DLL4 is a 685 amino acid single pass type 1 transmembrane glycoprotein of ~72 kDa containing a single DSL domain and eight EGF-like domains. Human DLL4 is the homologue of the Drosophila delta protein, and functions as a transmembrane bound ligand to the Notch receptor, Notch1.
DLL4 is expressed in the vasculature and plays a critical role in vascular development. It is induced by vascular endothelial growth factor (VEGF), as a negative feedback regulator to regulate angiogenic sprouting and promote the formation of a differentiated vascular network (Mailhos et al. 2001). DLL4 has been found to be strongly expressed in tumour vessels of primary renal tumours (Patel et al. 2005) and bladder cancer (Patel et al. 2006), and inhibition of DLL4 results in increased vascular proliferation but defective maturation. This in turn leads to a decrease in tumour growth, with no apparent toxicity (Ridgway et al. 2006).
Expression of DLL4 in normal human dermis is low in foetal tissues, becomes more intense during early life (0-20 years) and gradually declines thereafter as shown by immunohistochemical studies on FFPE tissues using rabbit anti human DLL4 antibody (Gunin et al. 2014).
DLL4 is expressed in the vasculature and plays a critical role in vascular development. It is induced by vascular endothelial growth factor (VEGF), as a negative feedback regulator to regulate angiogenic sprouting and promote the formation of a differentiated vascular network (Mailhos et al. 2001). DLL4 has been found to be strongly expressed in tumour vessels of primary renal tumours (Patel et al. 2005) and bladder cancer (Patel et al. 2006), and inhibition of DLL4 results in increased vascular proliferation but defective maturation. This in turn leads to a decrease in tumour growth, with no apparent toxicity (Ridgway et al. 2006).
Expression of DLL4 in normal human dermis is low in foetal tissues, becomes more intense during early life (0-20 years) and gradually declines thereafter as shown by immunohistochemical studies on FFPE tissues using rabbit anti human DLL4 antibody (Gunin et al. 2014).
Product Details
- Target Species
- Human
- Species Cross-Reactivity
-
Target Species Cross Reactivity Mouse Expected from Sequence Rat Expected from Sequence Chimpanzee Expected from Sequence - N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Antiserum Preparation
- Antisera to DLL4 were raised by repeated immunisations of rabbits with highly purified antigen. Purified IgG was prepared by affinity chromatography.
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Immunogen
- Synthetic peptide corresponding to the internal region of human DLL4.
- Approx. Protein Concentrations
- IgG concentration 0.5 mg/ml
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 18 months from date of despatch.
More Information
- UniProt
- Q9NR61 Related reagents
- Entrez Gene
- DLL4 Related reagents
- GO Terms
- GO:0005886 plasma membrane
- GO:0005509 calcium ion binding
- GO:0016021 integral to membrane
- GO:0005112 Notch binding
- GO:0007154 cell communication
- GO:0007219 Notch signaling pathway
- GO:0007220 Notch receptor processing
- GO:0008015 blood circulation
- GO:0030154 cell differentiation
- Regulatory
- For research purposes only
Applications of Delta-Like Protein 4 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | 1/3000 | 1/15000 | |
| Immunohistology - Paraffin | 5 | 15ug/ml | |
| Western Blotting | 1/300 | 1/1500 |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Histology Positive Control Tissue
- Human ovary.
- Western Blotting
- AHP1274 detects a band of approximately 74kDa in pancreatic cell lysates.
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Sheep anti Rabbit IgG:Biotin | 2AB02B | C E P WB | 1 ml |
|
|
| Goat anti Rabbit IgG (Fc):Biotin | STAR121B | E WB | 1 mg |
|
|
| Goat anti Rabbit IgG (Fc):FITC | STAR121F | F | 1 mg |
|
|
| Goat anti Rabbit IgG (Fc):HRP | STAR121P | E WB | 1 mg |
|
|
| Goat anti Rabbit IgG (H/L):HRP | STAR124P | C E WB | 1 mg |
|
|
| Sheep anti Rabbit IgG:FITC | STAR34B | C F | 1 mg |
|
|
| Sheep anti Rabbit IgG:RPE | STAR35A | F | 1 ml |
|
|
| Sheep anti Rabbit IgG:DyLight®488 | STAR36D488GA | F IF WB | 0.1 mg |
|
|
| Sheep anti Rabbit IgG:DyLight®680 | STAR36D680GA | F IF WB | 0.1 mg |
|
|
| Sheep anti Rabbit IgG:Dylight®800 | STAR36D800GA | F IF WB | 0.1 mg |
|
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Antigen Retrieval Buffer, pH8.0 | BUF025A | P | 500 ml | ||
| Antigen Retrieval Buffer, pH8.0 | BUF025C | P | 50 ml | ||
| TidyBlot Western Blot Detection Reagent:HRP | STAR209P | WB* | 0.5 ml |
Product Specific References
References for Delta-Like Protein 4 antibody
-
You, C. et al. (2013) Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations.
J Cell Mol Med. 17 (3): 407-18. -
Villaamil, V.M. et al. (2012) Multiple biomarker tissue arrays: A computational approach to identifying protein-protein interactions in the EGFR/ERK signalling pathway.
J Mol Signal. 7: 14. -
Gunin, A.G. et al. (2014) Age-related changes in angiogenesis in human dermis.
Exp Gerontol. 55C: 143-51. -
El Hindy, N. et al. (2013) Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme.
Neuro Oncol. 15: 1366-78. -
Medina Villaamil, V. et al. (2012) Searching for Hif1-α interacting proteins in renal cell carcinoma.
Clin Transl Oncol. 14: 698-708. -
Gunin, A.G. et al. (2014) Age-related changes in angiogenesis in human dermis.
Exp Gerontol. 55: 143-51. -
Hjelmgren O et al. (2016) Increased Vascularization in the Vulnerable Upstream Regions of Both Early and Advanced Human Carotid Atherosclerosis.
PLoS One. 11 (12): e0166918.
Further Reading
-
Thurston, G. et al. (2007) The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.
Nat Rev Cancer. 7 (5): 327-31.
